Anophthalmia-hypothalamo-pituitary insufficiency syndrome

Anophthalmia-hypothalamo-pituitary insufficiency syndrome is an extremely rare congenital disorder characterized by the combination of anophthalmia (absence of one or both eyes) or severe microphthalmia (abnormally small eyes) with hypothalamic-pituitary dysfunction. The condition is present from birth and reflects abnormal development of structures derived from the forebrain during embryogenesis. The hypothalamic-pituitary insufficiency can manifest as deficiencies in multiple pituitary hormones, including growth hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, and gonadotropins, leading to growth failure, hypothyroidism, adrenal insufficiency, and hypogonadism. Affected individuals typically present in the neonatal period with absent or severely underdeveloped eyes and signs of hormonal deficiency such as hypoglycemia, poor feeding, and failure to thrive. Additional features may include intellectual disability and other midline brain abnormalities. Some cases have been associated with mutations in genes involved in early eye and brain development, including SOX2 and OTX2, which play critical roles in forebrain and ocular morphogenesis. Management is multidisciplinary and primarily supportive. Hormone replacement therapy is essential to address pituitary insufficiency, including growth hormone, thyroid hormone, cortisol, and sex steroids as needed. Ophthalmologic management may include conformers or prosthetic eyes to promote normal orbital growth and cosmetic appearance. Early diagnosis and prompt initiation of hormone replacement are critical to prevent life-threatening adrenal crises and to optimize growth and neurodevelopmental outcomes. There is currently no curative treatment for this syndrome.

Common questions about Anophthalmia-hypothalamo-pituitary insufficiency syndrome